These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 38822977)
1. Multi-index comprehensive evaluation of the efficacy and response mechanism of immunotherapy in non-small cell lung cancer. Fan J; Zhang T Clin Transl Oncol; 2024 Dec; 26(12):3124-3130. PubMed ID: 38822977 [TBL] [Abstract][Full Text] [Related]
2. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer. Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405 [No Abstract] [Full Text] [Related]
3. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation. Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094 [No Abstract] [Full Text] [Related]
4. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy. Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008 [TBL] [Abstract][Full Text] [Related]
5. LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes. He Y; Yu H; Rozeboom L; Rivard CJ; Ellison K; Dziadziuszko R; Suda K; Ren S; Wu C; Hou L; Zhou C; Hirsch FR J Thorac Oncol; 2017 May; 12(5):814-823. PubMed ID: 28132868 [TBL] [Abstract][Full Text] [Related]
6. The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt. Bahnassy AA; Ismail H; Mohanad M; El-Bastawisy A; Yousef HF J Egypt Natl Canc Inst; 2022 May; 34(1):23. PubMed ID: 35644823 [TBL] [Abstract][Full Text] [Related]
7. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy. Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230 [TBL] [Abstract][Full Text] [Related]
8. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients. El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185 [TBL] [Abstract][Full Text] [Related]
9. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion. Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K Lung Cancer; 2019 Jan; 127():59-65. PubMed ID: 30642552 [TBL] [Abstract][Full Text] [Related]
10. Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation. Zhang B; Zeng J; Zhang H; Zhu S; Wang H; He J; Yang L; Zhou N; Zu L; Xu X; Song Z; Xu S Front Immunol; 2022; 13():974581. PubMed ID: 36159860 [TBL] [Abstract][Full Text] [Related]
11. Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in Peng XX; Yu R; Wu X; Wu SY; Pi C; Chen ZH; Zhang XC; Gao CY; Shao YW; Liu L; Wu YL; Zhou Q J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959728 [TBL] [Abstract][Full Text] [Related]
12. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA; Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095 [TBL] [Abstract][Full Text] [Related]
13. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer. Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698 [TBL] [Abstract][Full Text] [Related]
14. The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy. Kim SR; Chun SH; Kim JR; Kim SY; Seo JY; Jung CK; Gil BM; Kim JO; Ko YH; Woo IS; Shim BY; Hong SH; Kang JH BMC Cancer; 2021 Jan; 21(1):19. PubMed ID: 33402127 [TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphisms of GSTP1, XRCC1, XPC and ERCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer patients of Bangladesh. Bushra MU; Rivu SF; Sifat AE; Nahid NA; Ahmed MU; Al-Mamun MMA; Apu MNH; Islam MS; Islam MR; Islam MS; Hasnat A Mol Biol Rep; 2020 Sep; 47(9):7073-7082. PubMed ID: 32880833 [TBL] [Abstract][Full Text] [Related]
16. [Effect of the XRCC1 and XRCC3 genetic polymorphisms on the efficacy of platinum-based chemotherapy in patients with advanced non-small cell lung cancer]. Xu C; Wang X; Zhang Y; Li L Zhongguo Fei Ai Za Zhi; 2011 Dec; 14(12):912-7. PubMed ID: 22152690 [TBL] [Abstract][Full Text] [Related]
17. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum. Liao WY; Ho CC; Tsai TH; Chen KY; Shih JY; Yu CJ Lung Cancer; 2018 Apr; 118():90-96. PubMed ID: 29572009 [TBL] [Abstract][Full Text] [Related]
18. Real-world evidenceand clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors. Song P; Zhang J; Shang C; Zhang L Sci Rep; 2019 Mar; 9(1):4278. PubMed ID: 30862891 [TBL] [Abstract][Full Text] [Related]
19. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. Gainor JF; Shaw AT; Sequist LV; Fu X; Azzoli CG; Piotrowska Z; Huynh TG; Zhao L; Fulton L; Schultz KR; Howe E; Farago AF; Sullivan RJ; Stone JR; Digumarthy S; Moran T; Hata AN; Yagi Y; Yeap BY; Engelman JA; Mino-Kenudson M Clin Cancer Res; 2016 Sep; 22(18):4585-93. PubMed ID: 27225694 [TBL] [Abstract][Full Text] [Related]
20. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]